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studies on hta agencies
ag1
the geRman nice oR the geRman nasty? an analysis of iqwig 
decisions and RequiRements foR an ‘added benefit'
Griffiths EA
PAREXEL, London, UK
Objectives: IQWiG (The Institute for Quality and Economic Efficiency in Health 
Care or Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen) 
assesses the added benefit of new medicines in Germany, with stringent evidence 
requirements. To inform future submissions, all IQWiG decisions from January 2011 
to May 2015 were assessed, and the effect of the clinical evidence base on the sub-
mission outcome was examined. MethOds: All completed IQWiG drug appraisals 
from January 2011 to May 2015 were included in the analysis. Multiple-technology 
appraisals, non-drug intervention appraisals, and incomplete assessments were 
excluded. The recommendation (‘added benefit’ or ‘no added benefit’), indica-
tion, underlying rationale, and evidence base presented were extracted. Results: 
Between 2011 and May 2015, IQWiG published 132 drug appraisals, including 30 
resubmission/addendums. 50/132 (38%) of the appraisals were deemed to offer an 
added benefit (14% in all subpopulations; 24% in some subpopulations only), while 
82/132 (62%) of appraisals received a ‘no added benefit’ decision. Only 2/34 (6%) 
of appraisals lacking head-to-head evidence received an ‘added benefit’ decision, 
compared with 47/84 (56%) of appraisals reporting head-to-head evidence against an 
appropriate comparator and 0/14 (0%) of appraisals reporting head-to-head evidence 
against an inappropriate comparator. Oncologics, infectious disease drugs, and car-
diovascular drugs had the highest proportion of submissions receiving an ‘added 
benefit’ decision. Over time, the proportion of submissions receiving a ‘no added 
benefit decision’ has increased, from 50% (4/8) in 2011, to 52% (12/23) in 2012, 65% 
(26/40) in 2013, 64% (27/42) in 2014, and 68% (13/19) so far in 2015. cOnclusiOns: 
Over half of drugs appraised by IQWiG since 2011 have been given ‘no added benefit’ 
status, and direct evidence against an appropriate comparator remains a priority for 
a favourable decision. In contrast, NICE has rejected just 15% of technology appraisal 
submissions since its inception in 2000, highlighting the differences between the 
two agencies.
ag2
do evidence Review gRouPs bias nice decisions?
Versoza L, Jaksa A, Liden D, Ho Y
Context Matters, New York, NY, USA
Objectives: NICE designates one of nine independent academic centers as an 
Evidence Review Group(ERG) or Assessment Group(AG) to systematically review 
the clinical efficacy and cost-effectiveness of a product or products based on 
a manufacturer-submitted dossier or on published evidence. The ERG/AG’s 
report is integral to NICE’s decision-making process. This presentation explores 
whether NICE appraisals—particularly final reimbursement decisions—vary based 
on which ERG/AG was consulted. This evaluation is important from policy and 
industry perspectives as it can demonstrate whether NICE’s choice of ERG/AG 
is a potential source of bias in the technology appraisal process. To explore this 
topic, we examine clinical and economic factors within NICE appraisals influ-
enced by different ERG/AGs. MethOds: Reimbursement decision, therapeutic 
area (TA), manufacturer base-case ICER, NICE’s most plausible ICER, and clini-
cal and economic rationales for decision were extracted from NICE technology 
appraisal guidances from 2003-present. These factors were compared across ERG/
AGs. Results: NICE reviewed a total of 305 indications, with 72% resulting in posi-
tive decisions. Eleven different ERG/AGs were commissioned. There was no differ-
ence in rates of positive decisions between the different ERG/AGs (p= .69) though 
there was a wide range (mean = 72% [71% - 89%]). BMJ had the lowest rate of posi-
tive decisions and Warwick Evidence had the highest. There were differences in 
the number of oncology drugs reviewed by ERG/AG: Kleijnen Systematic Reviews 
assessed the most (60%) while Aberdeen HTA Group evaluated the fewest (4.6%). 
The presentation will show rates of positive decisions and clinical and economic 
rationales for decision by ERG/AG while controlling for TA. The presentation will 
also compare the most plausible ICERs and manufacturer base-case ICERs by ERG/
AG. cOnclusiOns: This study is the first systematic investigation of the influence 
of ERG/AGs on NICE reimbursement decisions. We will examine the components 
of the clinical and economic assessments as well as reimbursement decisions by 
ERG/AG.
abstRacts
ag3
the canceR dRugs fund in england – undeRmining nice oR efficient 
and good value foR money?
Harries M, Marshall JD, Stewart D
MAP BioPharma Limited, Cambridge, UK
Objectives: Since its inception in 2010, the National Cancer Drugs Fund (NCDF) 
has become an important market access route for cancer medicines in England and 
became fully established in April 2011. The objective of this analysis was to review 
the decisions made by the NCDF to date, in the context of NICE decisions, and iden-
tify how recent and proposed changes to the NCDF might impact on future decisions 
and the evaluation process for oncology products. MethOds: The NCDF list was 
analysed and compared against those appraised by NICE to obtain the percentage 
that are rejected by NICE as well as those that are never assessed by NICE. Trends 
across indications and the number of drugs represented on the NCDF were also 
analysed. Policy documents and consultations on proposed process changes to the 
NCDF were also reviewed. Results: As of May 2015 there are 38 drugs covering 67 
indications approved on the NCDF list, many of which have been rejected by NICE. 
Recently implemented and proposed changes such as a change to the definition 
of rarity when scoring the median drug cost per patient, and the appeal process, 
could have significant implications for pharmaceutical companies and patients on 
gaining reimbursement for oncology products. cOnclusiOns: The existence of 
the NCDF suggests that NHS England sees cancer as having more value than other 
diseases. Evidence suggests that the NCDF has been a success in providing access 
to medicines for patients but could be seen as undermining the NICE evaluation 
process. Recent changes in the NCDF appear to try and close this gap.
ag4
inflation, inflexibility and iRRelevance – the need foR inflation to 
be accounted foR in iceR thResholds
Macaulay R, Udechuku A
PAREXEL, London, UK
Objectives: Many obligate cost-utility Health Technology Assessment (HTA) bod-
ies formally or informally reference incremental cost-effectiveness ratio (ICER) 
thresholds as key criteria that new medicines must satisfy to receive reimburse-
ment approval. One such body, the National Institute of Health and Care Excellence 
(NICE), in 2004 defined its ICER threshold at £20,000 per quality added life year 
(QALY), rising to a maximum of £30,000/QALY if specific exceptional circumstances 
applied. Nevertheless, this basic threshold range has remained unaltered and has 
not accounted for inflation, the rate at which the general level of prices for goods 
and services rises. This research aims to model how the NICE threshold would vary 
if it fluctuated in line with the UK inflation rate and what effect this could have on 
appraisal outcomes. MethOds: Annual UK historical and forecast inflation rates 
were sourced from rateinflation.com (2004- 2016), upon which the effects on the 
NICE thresholds were modelled. Base-case ICERs were extracted from NICE Single 
Technology Appraisal (STA) reports for oncologics from 2006-July 2014. Results: 
Annual UK inflation rates varied from 0.4% to 4.5% (average 2.4%). Cumulatively, this 
amounts to a 29% decrease in the value of UK currency in this period. This means 
that in 2016 the NICE thresholds would need to rise to £26,100 and £39,150 to be 
monetarily equivalent to their 2004 levels. 60 NICE STA reports with base-case ICERs 
were extracted (average $68,636/QALY, range: US$5,390-234,009/QALY), 27 of which 
(45%) were not recommended. 35% (23/65) had a base-case ICER below £30,000 but 
this increased to 52% (34/65) if the £39,150 threshold is utilised. cOnclusiOns: 
The cumulative effects of inflation over time can be substantial. HTA bodies are 
artificially raising this threshold by not accounting for this fall in the currency 
purchasing power over time. ICER thresholds should be subject to periodic updat-
ing to account for inflation.
canceR outcomes ReseaRch studies
ca1
analysis of the RelationshiP between Patient-RePoRted outcomes 
(PRos) and clinical outcomes in metastatic castRation-Resistant 
PRostate canceR (mcRPc) Patients without PRioR chemotheRaPy
Traina S1, Li T1, Johnson K1, Ho KF2, Molina A3, Cella D4
1Janssen Research & Development, Raritan, NJ, USA, 2STAT-TU Inc., Toronto, ON, Canada, 
3Janssen Research & Development, Menlo Park, CA, USA, 4Northwestern University Feinberg 
School of Medicine, Chicago, IL, USA
Objectives: PROs are used in prostate cancer clinical trials to measure thera-
peutic impact. We explored the temporal relationship between changes in PROs 
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ca4
PRedictoRs of Positive decision outcomes by the canceR dRugs fund
Smith NJ1, Beckerman R2
1CBPartners, New York, NY, USA, 2Maple Health Group, LLC, New York, NY, USA
Objectives: To build a predictive model of acceptance of drugs to the United 
Kingdom’s (UK) Cancer Drugs Fund (CDF) based on the scores for each factor 
published in the public decision summaries. MethOds: All decision summaries 
published from December 2014 until May 2015 were included. For each decision 
summary, data were collected regarding the drug indication, scores for each decision 
factor (progression-free survival: PFS, overall survival: OS, quality-of-life: QoL, and 
unmet need), total clinical score, strength of evidence, cost, and decision outcome. 
Decisions to either retain or place drugs on formulary were counted as positive 
decisions; all other decisions were classified as negative decisions. A generalised 
linear model (GLM) was used to estimate the odds of each factor resulting in a 
positive decision; univariate and multivariate analyses were performed. Results: 
62 decisions were issued in the study period for a total of 34 different drugs; 2 
drugs were not formally assessed due to a lack of comparison against the standard 
of care in the UK. Only 22 of 64 (34.4%) of drugs received positive decisions from 
the CDF since December 2014, with an average total clinical score of 2.85. Median 
PFS and OS scores were 2 and 0, respectively, indicating most drugs did not have 
significantly improved OS as assessed by the CDF. Univariate results from the GLM 
demonstrated that PFS and OS gains resulted in higher odds of approval with odds 
ratios of 1.56 (95%CI:1.15-2.22) and 1.63 (95%CI:1.11-2.71), respectively. A multivariate 
analysis also demonstrated significant effects of PFS (OR:2.12,95%CI:1.43-3.50), OS 
(OR:2.35,95%CI:1.19-6.97), and a trend for QoL (OR:2.58,95%CI:0.73-9.93). Monthly 
cost was not a significant predictor of outcome in the model. cOnclusiOns: The 
majority of decisions since the 2015-2016 CDF procedures update have been nega-
tive; greater gains in PFS and OS significantly improved the likelihood of a positive 
CDF review outcome.
medical device & diagnostic ReseaRch studies
md1
medical devices: have health technology assessment agencies 
staRted to focus moRe on them?
Lie X1, Es-Skali IJ1, Gubbels L1, Nijhuis T1, Freeman C2
1Quintiles Advisory Services, Hoofddorp, The Netherlands, 2Quiniles Advisory Services, Reading, 
UK
Objectives: Since 2011, the number of health technology assessments (HTAs) on 
pharmacological therapies increases annually. As countries worldwide are trying 
to curb overall healthcare expenditure, the objective of this study was to analyse 
if this upward trend is also found in the area of medical devices. MethOds: One 
hundred HTA agencies were selected. Their reports on medical devices since 2011 
were analyzed by number and type and matched with HTAs for pharmacological 
therapies. Results: Not all of the included agencies assess medical devices. Most 
device HTAs are carried out in the UK, France, Sweden, the US and Australia, match-
ing their overall high HTA activity. However, other countries with high drug HTA 
activity (Germany, Spain, the Netherlands) focus less on devices. Most device-related 
HTAs are indicated for cardiovascular diseases, while pharmaceuticals are domi-
nated by oncology. The number of HTAs on pharmacological therapies increases 
every year (with seasonality), while the number of device HTAs remained steady over 
the last 5 years. Generally, HTA agencies seem to perform device evaluations more 
on an ad-hoc basis. cOnclusiOns: Although the total number of HTAs performed 
worldwide is increasing, the number of device assessments remained fairly stable. 
However, manufacturers seem to realize HTA importance and need to adapt to EU 
regulations. The increased clinical requirements in the draft EU Medical Devices 
Regulation will enable manufacturers to find their role in this growing area.
md2
the cost of moleculaR diagnostic testing in oncology – a 
woRkflow analysis
Bellosillo B1, Pages J2, Collin C2, Pasmans R3, Montagut C4
1Department of Pathology, Hospital del Mar, Barcelona, Spain, 2Laboratoire de Biochimie et Biologie 
Moléculaire, CHRU Trousseau, Tours, France, 3Biocartis NV, Mechelen, Belgium, 4Medical Oncology 
Department, Hospital del Mar, Barcelona, Spain
Objectives: The rise in molecular diagnostic testing in oncology has made these 
tests the subject of an increasing number of investment discussions, reimbursement 
negotiations and hospital cost calculations. This requires a detailed assessment 
of the total cost for determining tumor mutation status beyond plain kit costs. 
This research maps the workflow, identifies investment needs and quantifies the 
direct variable costs of KRAS and NRASmutation testing from formalin fixed paraf-
fin embedded (FFPE) sample to result. MethOds: The complete test workflow is 
based on the current workflow in two academic European institutions. Hands-on 
time and consumables used in each step were quantified in both hospitals. Unit 
cost was obtained from the finance departments. Results: Costs related to tumor 
mutation tests include investments (lab space, lab equipment, molecular diagnostic 
systems, training, quality assurance, accreditation), indirect costs, lab running costs 
(disinfection, cost of errors and repeats) and direct variable costs including reagent 
costs, controls and labor. The total cost depends on workflow and tumor profile. To 
detect a wild-type RAS tumor, the direct variable costs from FFPE sample to result 
excluding reagent costs, is estimated at € 64 using a CE-IVD kit for KRAS exon 2 
followed by pyrosequencing for NRAS exon 2 and extended RAS testing, € 51 using 
High Resolution Melting confirmed by pyrosequencing and € 3 for an automated 
instrument. The latter automated technology includes sample preparation in the 
test cost, as it works directly from FFPE. cOnclusiOns: Estimations on the cost 
of performing tumor mutation tests should include not only reagent costs, which 
are usually considered, but also investments, lab running costs, labor and all other 
direct and indirect costs. Even in the most advanced labs, efforts are needed to fully 
and subsequent clinical outcomes in chemotherapy-naïve mCRPC. MethOds: 
COU-AA-302 was a multinational, double-blind, randomized phase 3 trial of abira-
terone acetate plus prednisone compared with prednisone alone in asymptomatic 
or mildly symptomatic mCRPC patients without previous chemotherapy. Using 
data from the entire COU-AA-302 patient population (N = 1088) over the first 181 
days of treatment, we explored the relationships between clinical time-to-event 
end points and changes in PROs measuring pain, physical well-being (PWB), func-
tional well-being (FWB), and prostate cancer–specific signs and symptoms. Cox 
regression models were developed to assess the relationship between each PRO 
(separately and for all 4 simultaneously), and radiographic progression-free survival 
(rPFS) as the dependent variable, adjusting for important baseline clinical and PRO 
characteristics. Results: In each individual model, patients with worsening PROs 
were at greater risk of radiographic progression compared with patients whose 
PRO scores improved or remained stable during the follow-up period. Hazard ratios 
(95% confidence intervals) for worsening pain intensity, PWB, FWB, and prostate 
cancer–specific symptoms were 1.68 (1.28-2.21), 2.08 (1.60-2.71), 1.35 (1.04-1.74), and 
1.52 (1.18-1.95), respectively (all p ≤ 0.02). When all 4 PRO end points were included 
in a single multivariate model, a worsening in PWB was the most significant factor 
associated with worse rPFS. There were too few events at the time of analysis cut-
off to explore the relationship between survival and PROs. cOnclusiOns: These 
results demonstrate a significant temporal relationship between PROs and disease 
progression. Worsening of PROs was associated with an increased likelihood of 
radiographic progression. In addition to their traditional utility in describing patient-
relevant outcomes in clinical trials, PROs may be valuable clinical monitoring tools 
when following patients for disease progression.
ca2
the esmo magnitude of clinical benefit scale foR novel canceR 
medicines — coRResPondence with PRioRitization decisions in 
uPdating the isRaeli national list of health seRvices
Hammerman A1, Greenberg-Dotan S1, Feldhamer I1, Birnbaum Y1, Cherny NI2
1Clalit Health Services, Tel-Aviv, Israel, 2Shaare-Zedek Medical Center, Jerusalem, Israel
Objectives: The Israeli National Health Insurance Law stipulates a National List 
of Health Services (NLHS) which all residents are entitled to. Every year, the govern-
ment determines the additional budget to be allocated for new health technologies 
on the NLHS. A public national advisory committee (PNAC) evaluates and prioritizes 
all proposed technologies. The PNAC takes into account mainly the efficacy of the 
new technology, but also economic, social and ethical aspects. However, until now, 
no standard tool was available for grading the extent of benefit of therapies. The 
European Society for Medical Oncology (ESMO) published recently its Magnitude 
of Clinical Benefit Scale (ESMO-MCBS) for cancer medicines. The scale is graded 5, 
4, 3, 2, 1, for treatments of advanced/metastatic cancers (the ‘palliative setting’), 
where grades 5 and 4 represent the highest level of proven clinical benefit. Our 
objective was to examine, in retrospect, whether the novel cancer drugs that were 
recommended for reimbursement by the PNAC, had higher ESMO-MCBS scores 
than the candidate drugs that were not approved in the 2015 NLHS update pro-
cess. MethOds: ESMO-MCBS scores were obtained for the cancer drugs that were 
candidates for the 2015 NLHS update. Fisher’s Exact Test was used to compare scores 
of drugs approved and those not approved for reimbursement. Results: 17 cancer 
drugs were candidates for the 2015 NLHS update deliberations. An ESMO-MCBS 
score was available for 5/7 approved drugs and 8/10 non-approved drugs. 80% of the 
approved drugs and none of the non-approved drugs gained a score> = 3 (p= 0.007). 
Median scores were 3 and 1 respectively. cOnclusiOns: The Israeli PNAC’s deci-
sions regarding reimbursement for novel cancer drugs seem to be in concordance 
with ESMO-MCBS scores. The structured and consistent approach of the ESMO-
MCBS could further assist in framing the appropriate use of limited public resources 
to deliver effective and affordable cancer care.
ca3
the buRden of canceR in emeRging economies: PRoductivity loss as 
an alteRnative PeRsPective
Pearce A1, Hanly P2, Sharp L3, Soerjomataram I4
1National Cancer Registry Ireland, Cork, Ireland, 2National College of Ireland, Dublin, Ireland, 
3Newcastle University, Newcastle, UK, 4International Agency for Research on Cancer, Lyon, France
Objectives: When people die due to cancer, their contribution to society through 
paid work, called production, is lost. Previous estimates of cancer-related lost 
production have focussed on developed countries. However, developing nations 
account for approximately 70% of the world’s annual cancer deaths. We estimate 
the value of lost productivity due to cancer mortality in the rapidly emerging econo-
mies of Brazil, Russia, India, China and South Africa (BRICS) and compare it to 
the UK. MethOds: Based on the Human Capital Approach, we valued the lost 
productivity associated with premature cancer deaths in BRICS countries and the 
UK in 2012. We used GLOBOCAN estimates of cancer deaths by country, sex and 
age group, along with OECD and national data for workforce participation, unem-
ployment, and wage rates. Sensitivity analyses examined the impact of changing 
assumptions about wages, life expectancy and discounting. Results: The total 
cost of cancer-related lost productivity in the UK in 2012 was € 3 billion, and in 
the BRICS countries combined was over € 24 billion. Losses were highest in China 
(€ 12.9 billion) and lowest in South Africa (€ 0.9 billion). When adjusted by number of 
deaths, lost productivity (per death) were highest in South Africa (€ 19,000), the UK 
(€ 19,000), and Brazil (€ 14,000) and lowest in India (€ 3,000). There were large differ-
ences between countries in terms of lost productivity when examined by gender, age 
and cancer. For example, the cancers contributing highest productivity losses were 
lung cancer in Russia (22% of total), South Africa (14%), Brazil (13%) and the UK (11%), 
stomach cancer in India (11%), and liver cancer in China (31%). cOnclusiOns: 
In many developing countries cancer now kills more people than AIDS, malaria 
and tuberculosis combined, however resources have not shifted correspondingly. 
Valuing cancer-related lost productivity provides policy-makers with an additional 
perspective on priorities for cancer prevention and control.
